LONG-TERM FOLLOW UP OF ACUTE HEART FAILURE PATIENTS UNDERWENT LEVOSIMENDAN INFUSION: IDENTIFICATION OF RESPONDERS AND NON-RESPONDERS BY USING HLM CLASSIFICATION

Background Levosimendan (Levo) reduces mortality in Acute Heart Failure (AHF) that determines involvement of other organs beyond heart; similar to TNM used in oncology, we proposed HLM staging system to assess prognosis of HF patients evaluating heart damage (H), lung involvement (L) and malfunction (M) of peripheral organs. The aim is to evaluate the outcomes of Levo infusion in AHF patients and identify the predictors of cardiac mortality and rehospitalization for major cardiovascular and cerebrovascular events (MACCE) by using HLM classification Methods All 300 AHF enrolled patients received 24h Levo iv infusion (0.05- 0.2 μg/kg/min, no bolus) in addition to standard therapy.